Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 246

1.

Frequency of Pathogenic Germline Variants in CDH1, BRCA2, CHEK2, PALB2, BRCA1, and TP53 in Sporadic Lobular Breast Cancer.

Petridis C, Arora I, Shah V, Moss CL, Mera A, Clifford A, Gillett C, Pinder SE, Tomlinson I, Roylance R, Simpson MA, Sawyer EJ.

Cancer Epidemiol Biomarkers Prev. 2019 Jul;28(7):1162-1168. doi: 10.1158/1055-9965.EPI-18-1102.

PMID:
31263054
2.

Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years.

Petridis C, Arora I, Shah V, Megalios A, Moss C, Mera A, Clifford A, Gillett C, Pinder SE, Tomlinson I, Roylance R, Simpson MA, Sawyer EJ.

Breast Cancer Res. 2019 May 6;21(1):58. doi: 10.1186/s13058-019-1143-y.

3.

Molecular patterns of cancer colonisation in lymph nodes of breast cancer patients.

Chatterjee G, Pai T, Hardiman T, Avery-Kiejda K, Scott RJ, Spencer J, Pinder SE, Grigoriadis A.

Breast Cancer Res. 2018 Nov 20;20(1):143. doi: 10.1186/s13058-018-1070-3. Review.

4.

Management and 5-year outcomes in 9938 women with screen-detected ductal carcinoma in situ: the UK Sloane Project.

Thompson AM, Clements K, Cheung S, Pinder SE, Lawrence G, Sawyer E, Kearins O, Ball GR, Tomlinson I, Hanby A, Thomas JSJ, Maxwell AJ, Wallis MG, Dodwell DJ; Sloane Project Steering Group (NHS Prospective Study of Screen-Detected Non-invasive Neoplasias).

Eur J Cancer. 2018 Sep;101:210-219. doi: 10.1016/j.ejca.2018.06.027. Epub 2018 Aug 6.

PMID:
30092498
5.

NHS Breast Screening multidisciplinary working group guidelines for the diagnosis and management of breast lesions of uncertain malignant potential on core biopsy (B3 lesions).

Pinder SE, Shaaban A, Deb R, Desai A, Gandhi A, Lee AHS, Pain S, Wilkinson L, Sharma N.

Clin Radiol. 2018 Aug;73(8):682-692. doi: 10.1016/j.crad.2018.04.004.

PMID:
29773220
6.

Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.

Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, Owen J, Abraham J, Barrett S, Barrett-Lee P, Brown R, Chan S, Dowsett M, Flanagan JM, Fox L, Grigoriadis A, Gutin A, Harper-Wynne C, Hatton MQ, Hoadley KA, Parikh J, Parker P, Perou CM, Roylance R, Shah V, Shaw A, Smith IE, Timms KM, Wardley AM, Wilson G, Gillett C, Lanchbury JS, Ashworth A, Rahman N, Harries M, Ellis P, Pinder SE, Bliss JM.

Nat Med. 2018 May;24(5):628-637. doi: 10.1038/s41591-018-0009-7. Epub 2018 Apr 30.

7.

Diagnostic concordance of reporting lymphovascular invasion in breast cancer.

Rakha EA, Abbas A, Pinto Ahumada P, ElSayed ME, Colman D, Pinder SE, Ellis IO.

J Clin Pathol. 2018 Sep;71(9):802-805. doi: 10.1136/jclinpath-2017-204981. Epub 2018 Mar 29.

PMID:
29599396
8.

The importance of histological assessment after neoadjuvant therapy and the need for standardisation.

Naidoo K, Pinder SE.

Clin Radiol. 2018 Aug;73(8):693-699. doi: 10.1016/j.crad.2018.01.005. Epub 2018 Feb 10. Review.

PMID:
29439778
9.

Histological scoring of immune and stromal features in breast and axillary lymph nodes is prognostic for distant metastasis in lymph node-positive breast cancers.

Grigoriadis A, Gazinska P, Pai T, Irhsad S, Wu Y, Millis R, Naidoo K, Owen J, Gillett CE, Tutt A, Coolen AC, Pinder SE.

J Pathol Clin Res. 2018 Jan 8;4(1):39-54. doi: 10.1002/cjp2.87. eCollection 2018 Jan.

10.

Risk factors for the development of invasive cancer in unresected ductal carcinoma in situ.

Maxwell AJ, Clements K, Hilton B, Dodwell DJ, Evans A, Kearins O, Pinder SE, Thomas J, Wallis MG, Thompson AM; Sloane Project Steering Group.

Eur J Surg Oncol. 2018 Apr;44(4):429-435. doi: 10.1016/j.ejso.2017.12.007. Epub 2018 Jan 11.

PMID:
29398324
11.

Pleomorphic LCIS what do we know? A UK multicenter audit of pleomorphic lobular carcinoma in situ.

Masannat YA, Husain E, Roylance R, Heys SD, Carder PJ, Ali H, Maurice Y, Pinder SE, Sawyer E, Shaaban AM.

Breast. 2018 Apr;38:120-124. doi: 10.1016/j.breast.2017.12.011. Epub 2018 Jan 5.

PMID:
29310036
12.

Invasion in breast lesions: the role of the epithelial-stroma barrier.

Rakha EA, Miligy IM, Gorringe KL, Toss MS, Green AR, Fox SB, Schmitt FC, Tan PH, Tse GM, Badve S, Decker T, Vincent-Salomon A, Dabbs DJ, Foschini MP, Moreno F, Wentao Y, Geyer FC, Reis-Filho JS, Pinder SE, Lakhani SR, Ellis IO.

Histopathology. 2018 Jun;72(7):1075-1083. doi: 10.1111/his.13446. Epub 2018 Feb 13. Review.

PMID:
29197112
13.

Gene expression modules in primary breast cancers as risk factors for organotropic patterns of first metastatic spread: a case control study.

Lawler K, Papouli E, Naceur-Lombardelli C, Mera A, Ougham K, Tutt A, Kimbung S, Hedenfalk I, Zhan J, Zhang H, Buus R, Dowsett M, Ng T, Pinder SE, Parker P, Holmberg L, Gillett CE, Grigoriadis A, Purushotham A.

Breast Cancer Res. 2017 Oct 13;19(1):113. doi: 10.1186/s13058-017-0881-y.

14.

High-intensity focused ultrasound in the treatment of breast fibroadenomata (HIFU-F trial).

Peek MCL, Ahmed M, Scudder J, Baker R, Charalampoudis P, Pinder SE, Douek M; HIFU-F Collaborators.

Int J Hyperthermia. 2018 Nov;34(7):1002-1009. doi: 10.1080/02656736.2017.1373865. Epub 2017 Oct 2.

PMID:
28854826
15.

Neoadjuvant Therapy in Early Breast Cancer: Treatment Considerations and Common Debates in Practice.

Cain H, Macpherson IR, Beresford M, Pinder SE, Pong J, Dixon JM.

Clin Oncol (R Coll Radiol). 2017 Oct;29(10):642-652. doi: 10.1016/j.clon.2017.06.003. Epub 2017 Jun 29. Review.

16.

Use of a handheld terahertz pulsed imaging device to differentiate benign and malignant breast tissue.

Grootendorst MR, Fitzgerald AJ, Brouwer de Koning SG, Santaolalla A, Portieri A, Van Hemelrijck M, Young MR, Owen J, Cariati M, Pepper M, Wallace VP, Pinder SE, Purushotham A.

Biomed Opt Express. 2017 May 9;8(6):2932-2945. doi: 10.1364/BOE.8.002932. eCollection 2017 Jun 1.

17.

Somatic mutations reveal asymmetric cellular dynamics in the early human embryo.

Ju YS, Martincorena I, Gerstung M, Petljak M, Alexandrov LB, Rahbari R, Wedge DC, Davies HR, Ramakrishna M, Fullam A, Martin S, Alder C, Patel N, Gamble S, O'Meara S, Giri DD, Sauer T, Pinder SE, Purdie CA, Borg Å, Stunnenberg H, van de Vijver M, Tan BK, Caldas C, Tutt A, Ueno NT, van 't Veer LJ, Martens JW, Sotiriou C, Knappskog S, Span PN, Lakhani SR, Eyfjörd JE, Børresen-Dale AL, Richardson A, Thompson AM, Viari A, Hurles ME, Nik-Zainal S, Campbell PJ, Stratton MR.

Nature. 2017 Mar 30;543(7647):714-718. doi: 10.1038/nature21703. Epub 2017 Mar 22.

18.

Discrepancies in central review re-testing of patients with ER-positive and HER2-negative breast cancer in the OPTIMA prelim randomised clinical trial.

Pinder SE, Campbell AF, Bartlett JM, Marshall A, Allen D, Falzon M, Dunn JA, Makris A, Hughes-Davies L, Stein RC.

Br J Cancer. 2017 Mar 28;116(7):859-863. doi: 10.1038/bjc.2017.28. Epub 2017 Feb 21.

19.

PIK3CA mutations are common in lobular carcinoma in situ, but are not a biomarker of progression.

Shah V, Nowinski S, Levi D, Shinomiya I, Kebaier Ep Chaabouni N, Gillett C, Grigoriadis A, Graham TA, Roylance R, Simpson MA, Pinder SE, Sawyer EJ.

Breast Cancer Res. 2017 Jan 17;19(1):7. doi: 10.1186/s13058-016-0789-y.

20.

RORγt+ Innate Lymphoid Cells Promote Lymph Node Metastasis of Breast Cancers.

Irshad S, Flores-Borja F, Lawler K, Monypenny J, Evans R, Male V, Gordon P, Cheung A, Gazinska P, Noor F, Wong F, Grigoriadis A, Fruhwirth GO, Barber PR, Woodman N, Patel D, Rodriguez-Justo M, Owen J, Martin SG, Pinder SE, Gillett CE, Poland SP, Ameer-Beg S, McCaughan F, Carlin LM, Hasan U, Withers DR, Lane P, Vojnovic B, Quezada SA, Ellis P, Tutt AN, Ng T.

Cancer Res. 2017 Mar 1;77(5):1083-1096. doi: 10.1158/0008-5472.CAN-16-0598. Epub 2017 Jan 12.

21.

Reply to R.F. Sweis et al.

Schmid P, Pinder SE, Purushotham A, Thompson AM.

J Clin Oncol. 2017 Jan 10;35(2):261-262. Epub 2016 Oct 31. No abstract available.

PMID:
28056198
22.

Diagnostic concordance of breast pathologists: lessons from the National Health Service Breast Screening Programme Pathology External Quality Assurance Scheme.

Rakha EA, Ahmed MA, Aleskandarany MA, Hodi Z, Lee AH, Pinder SE, Ellis IO.

Histopathology. 2017 Mar;70(4):632-642. doi: 10.1111/his.13117. Epub 2016 Dec 28.

PMID:
28028831
23.

Breast conservation in ductal carcinoma in situ (DCIS): what defines optimal margins?

Toss MS, Pinder SE, Green AR, Thomas J, Morgan DA, Robertson JF, Ellis IO, Rakha EA.

Histopathology. 2017 Apr;70(5):681-692. doi: 10.1111/his.13116. Epub 2016 Dec 20. Review.

PMID:
28000325
24.

Microstructural models for diffusion MRI in breast cancer and surrounding stroma: an ex vivo study.

Bailey C, Siow B, Panagiotaki E, Hipwell JH, Mertzanidou T, Owen J, Gazinska P, Pinder SE, Alexander DC, Hawkes DJ.

NMR Biomed. 2017 Feb;30(2). doi: 10.1002/nbm.3679. Epub 2016 Dec 21.

25.

Modern therapies and iatrogenic changes in breast pathology.

Provenzano E, Pinder SE.

Histopathology. 2017 Jan;70(1):40-55. doi: 10.1111/his.13098. Review.

PMID:
27960235
26.

The impact of human epidermal growth factor receptor 2 neoadjuvant monoclonal antibody (trastuzumab) therapy in ductal carcinoma in situ of the breast.

Parham DM, Pinder SE.

Histopathology. 2017 May;70(6):1009-1011. doi: 10.1111/his.13145. Epub 2017 Feb 7. No abstract available.

PMID:
27943389
27.

The B3 conundrum-the radiologists' perspective.

Sharma N, Wilkinson LS, Pinder SE.

Br J Radiol. 2017 Mar;90(1071):20160595. doi: 10.1259/bjr.20160595. Epub 2016 Dec 12. Review.

28.

Intraoperative Assessment of Tumor Resection Margins in Breast-Conserving Surgery Using 18F-FDG Cerenkov Luminescence Imaging: A First-in-Human Feasibility Study.

Grootendorst MR, Cariati M, Pinder SE, Kothari A, Douek M, Kovacs T, Hamed H, Pawa A, Nimmo F, Owen J, Ramalingam V, Sethi S, Mistry S, Vyas K, Tuch DS, Britten A, Van Hemelrijck M, Cook GJ, Sibley-Allen C, Allen S, Purushotham A.

J Nucl Med. 2017 Jun;58(6):891-898. doi: 10.2967/jnumed.116.181032. Epub 2016 Dec 8.

29.

HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status.

Weitsman G, Barber PR, Nguyen LK, Lawler K, Patel G, Woodman N, Kelleher MT, Pinder SE, Rowley M, Ellis PA, Purushotham AD, Coolen AC, Kholodenko BN, Vojnovic B, Gillett C, Ng T.

Oncotarget. 2016 Aug 9;7(32):51012-51026. doi: 10.18632/oncotarget.9963.

30.

Accuracy of classification of invasive lobular carcinoma on needle core biopsy of the breast.

Naidoo K, Beardsley B, Carder PJ, Deb R, Fish D, Girling A, Hales S, Howe M, Wastall LM, Lane S, Lee AH, Philippidou M, Quinn C, Stephenson T, Pinder SE.

J Clin Pathol. 2016 Dec;69(12):1122-1123. doi: 10.1136/jclinpath-2016-203886. Epub 2016 Aug 10.

PMID:
27510520
31.

Micro- and macro-metastasis in the axillary lymph node: A review.

Naidoo K, Pinder SE.

Surgeon. 2017 Apr;15(2):76-82. doi: 10.1016/j.surge.2016.07.002. Epub 2016 Aug 3. Review.

PMID:
27498412
32.

An audit of residual cancer burden reproducibility in a UK context.

Naidoo K, Parham DM, Pinder SE.

Histopathology. 2017 Jan;70(2):217-222. doi: 10.1111/his.13054. Epub 2016 Sep 27.

PMID:
27496095
33.

High intensity focused ultrasound in the treatment of breast fibroadenomata: results of the HIFU-F trial.

Peek MC, Ahmed M, Scudder J, Baker R, Pinder SE, Douek M; HIFU-F Trialists’ Group.

Int J Hyperthermia. 2016 Dec;32(8):881-888. Epub 2016 Sep 7.

PMID:
27484113
34.

Review of the national external quality assessment (EQA) scheme for breast pathology in the UK.

Rakha EA, Bennett RL, Coleman D, Pinder SE, Ellis IO; UK National Coordinating Committee for Breast Pathology (EQA Scheme Steering Committee).

J Clin Pathol. 2017 Jan;70(1):51-57. doi: 10.1136/jclinpath-2016-203800. Epub 2016 Jul 12.

PMID:
27406051
35.

Erratum: The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes.

Pereira B, Chin SF, Rueda OM, Vollan HK, Provenzano E, Bardwell HA, Pugh M, Jones L, Russell R, Sammut SJ, Tsui DW, Liu B, Dawson SJ, Abraham J, Northen H, Peden JF, Mukherjee A, Turashvili G, Green AR, McKinney S, Oloumi A, Shah S, Rosenfeld N, Murphy L, Bentley DR, Ellis IO, Purushotham A, Pinder SE, Børresen-Dale AL, Earl HM, Pharoah PD, Ross MT, Aparicio S, Caldas C.

Nat Commun. 2016 Jun 6;7:11908. doi: 10.1038/ncomms11908. No abstract available.

36.

Progression of breast cancer following locoregional ipsilateral recurrence: importance of interval time.

Melvin JC, Purushotham AD, Garmo H, Pinder SE, Fentiman IS, Gillett C, Mera A, Lüchtenborg M, Holmberg L, Van Hemelrijck M.

Br J Cancer. 2016 Jun 14;114(12):e23. doi: 10.1038/bjc.2016.135. Epub 2016 May 26. No abstract available.

37.

Two E-selectin ligands, BST-2 and LGALS3BP, predict metastasis and poor survival of ER-negative breast cancer.

Woodman N, Pinder SE, Tajadura V, Le Bourhis X, Gillett C, Delannoy P, Burchell JM, Julien S.

Int J Oncol. 2016 Jul;49(1):265-75. doi: 10.3892/ijo.2016.3521. Epub 2016 May 13.

PMID:
27176937
38.

The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes.

Pereira B, Chin SF, Rueda OM, Vollan HK, Provenzano E, Bardwell HA, Pugh M, Jones L, Russell R, Sammut SJ, Tsui DW, Liu B, Dawson SJ, Abraham J, Northen H, Peden JF, Mukherjee A, Turashvili G, Green AR, McKinney S, Oloumi A, Shah S, Rosenfeld N, Murphy L, Bentley DR, Ellis IO, Purushotham A, Pinder SE, Børresen-Dale AL, Earl HM, Pharoah PD, Ross MT, Aparicio S, Caldas C.

Nat Commun. 2016 May 10;7:11479. doi: 10.1038/ncomms11479.

39.

Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others.

Bartlett JM, Bayani J, Marshall A, Dunn JA, Campbell A, Cunningham C, Sobol MS, Hall PS, Poole CJ, Cameron DA, Earl HM, Rea DW, Macpherson IR, Canney P, Francis A, McCabe C, Pinder SE, Hughes-Davies L, Makris A, Stein RC; OPTIMA TMG.

J Natl Cancer Inst. 2016 Apr 29;108(9). pii: djw050. doi: 10.1093/jnci/djw050. Print 2016 Sep.

40.

The radiological features, diagnosis and management of screen-detected lobular neoplasia of the breast: Findings from the Sloane Project.

Maxwell AJ, Clements K, Dodwell DJ, Evans AJ, Francis A, Hussain M, Morris J, Pinder SE, Sawyer EJ, Thomas J, Thompson A; Sloane Project Steering Group.

Breast. 2016 Jun;27:109-15. doi: 10.1016/j.breast.2016.03.004. Epub 2016 Apr 6.

PMID:
27060553
41.

Viewpoint: Availability of oestrogen receptor and HER2 status for the breast multidisciplinary meeting discussion; time to get it right.

Francis A, Bartlett J, Rea D, Pinder SE, Stein RC, Stobart H, Purdie CA, Rakha E, Thompson A, Shaaban AM; Translational Subgroup of the NCRI Breast Clinical Studies Group.

Eur J Surg Oncol. 2016 Jul;42(7):994-8. doi: 10.1016/j.ejso.2016.02.015. Epub 2016 Mar 16.

PMID:
27020141
42.

Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast Cancer.

Schmid P, Pinder SE, Wheatley D, Macaskill J, Zammit C, Hu J, Price R, Bundred N, Hadad S, Shia A, Sarker SJ, Lim L, Gazinska P, Woodman N, Korbie D, Trau M, Mainwaring P, Gendreau S, Lackner MR, Derynck M, Wilson TR, Butler H, Earl G, Parker P, Purushotham A, Thompson A.

J Clin Oncol. 2016 Jun 10;34(17):1987-94. doi: 10.1200/JCO.2015.63.9179. Epub 2016 Mar 14.

43.

Genetic predisposition to ductal carcinoma in situ of the breast.

Petridis C, Brook MN, Shah V, Kohut K, Gorman P, Caneppele M, Levi D, Papouli E, Orr N, Cox A, Cross SS, Dos-Santos-Silva I, Peto J, Swerdlow A, Schoemaker MJ, Bolla MK, Wang Q, Dennis J, Michailidou K, Benitez J, González-Neira A, Tessier DC, Vincent D, Li J, Figueroa J, Kristensen V, Borresen-Dale AL, Soucy P, Simard J, Milne RL, Giles GG, Margolin S, Lindblom A, Brüning T, Brauch H, Southey MC, Hopper JL, Dörk T, Bogdanova NV, Kabisch M, Hamann U, Schmutzler RK, Meindl A, Brenner H, Arndt V, Winqvist R, Pylkäs K, Fasching PA, Beckmann MW, Lubinski J, Jakubowska A, Mulligan AM, Andrulis IL, Tollenaar RA, Devilee P, Le Marchand L, Haiman CA, Mannermaa A, Kosma VM, Radice P, Peterlongo P, Marme F, Burwinkel B, van Deurzen CH, Hollestelle A, Miller N, Kerin MJ, Lambrechts D, Floris G, Wesseling J, Flyger H, Bojesen SE, Yao S, Ambrosone CB, Chenevix-Trench G, Truong T, Guénel P, Rudolph A, Chang-Claude J, Nevanlinna H, Blomqvist C, Czene K, Brand JS, Olson JE, Couch FJ, Dunning AM, Hall P, Easton DF, Pharoah PD, Pinder SE, Schmidt MK, Tomlinson I, Roylance R, García-Closas M, Sawyer EJ.

Breast Cancer Res. 2016 Feb 17;18(1):22. doi: 10.1186/s13058-016-0675-7.

44.

OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer.

Stein RC, Dunn JA, Bartlett JM, Campbell AF, Marshall A, Hall P, Rooshenas L, Morgan A, Poole C, Pinder SE, Cameron DA, Stallard N, Donovan JL, McCabe C, Hughes-Davies L, Makris A; OPTIMA Trial Management Group.

Health Technol Assess. 2016 Feb;20(10):xxiii-xxix, 1-201. doi: 10.3310/hta20100.

45.

Immunohistochemistry for Triple-Negative Breast Cancer.

Naidoo K, Pinder SE.

Methods Mol Biol. 2016;1406:39-51. doi: 10.1007/978-1-4939-3444-7_3.

PMID:
26820943
46.

Family history of breast cancer and its association with disease severity and mortality.

Melvin JC, Wulaningsih W, Hana Z, Purushotham AD, Pinder SE, Fentiman I, Gillett C, Mera A, Holmberg L, Van Hemelrijck M.

Cancer Med. 2016 May;5(5):942-9. doi: 10.1002/cam4.648. Epub 2016 Jan 22.

47.

A review of ablative techniques in the treatment of breast fibroadenomata.

Peek MC, Ahmed M, Pinder SE, Douek M.

J Ther Ultrasound. 2016 Jan 19;4:1. doi: 10.1186/s40349-016-0045-z. eCollection 2016. Review.

48.

Progression of breast cancer following locoregional ipsilateral recurrence: importance of interval time.

Melvin JC, Purushotham AD, Garmo H, Pinder SE, Fentiman IS, Gillett C, Mera A, Lüchtenborg M, Holmberg L, Van Hemelrijck M.

Br J Cancer. 2016 Jan 12;114(1):88-95. doi: 10.1038/bjc.2015.314. Epub 2015 Dec 10. Erratum in: Br J Cancer. 2016 Jun 14;114(12):e23.

49.

PAK4 promotes kinase-independent stabilization of RhoU to modulate cell adhesion.

Dart AE, Box GM, Court W, Gale ME, Brown JP, Pinder SE, Eccles SA, Wells CM.

J Cell Biol. 2015 Nov 23;211(4):863-79. doi: 10.1083/jcb.201501072.

50.

Addressing overtreatment of screen detected DCIS; the LORIS trial.

Francis A, Thomas J, Fallowfield L, Wallis M, Bartlett JM, Brookes C, Roberts T, Pirrie S, Gaunt C, Young J, Billingham L, Dodwell D, Hanby A, Pinder SE, Evans A, Reed M, Jenkins V, Matthews L, Wilcox M, Fairbrother P, Bowden S, Rea D.

Eur J Cancer. 2015 Nov;51(16):2296-303. doi: 10.1016/j.ejca.2015.07.017. Epub 2015 Aug 18.

PMID:
26296293

Supplemental Content

Loading ...
Support Center